Treating hyperammonemia depends on how severe it is and what caused it, but the universal priority is the same: bring ammonia levels down fast enough to prevent brain damage. In an emergency, that means intravenous nitrogen-scavenging drugs, halting protein intake, and sometimes dialysis. Once the crisis passes, treatment shifts to maintaining safe ammonia levels through medications, dietary management, and addressing the underlying cause. The specifics vary widely depending on whether the hyperammonemia stems from liver disease, an inherited metabolic disorder, or a medication side effect, and those distinctions matter for every treatment decision along the way.
Why High Ammonia Is a Medical Emergency
Ammonia is a normal byproduct of protein metabolism, and a healthy liver converts it to urea for excretion through the kidneys. When that process breaks down, ammonia accumulates in the blood and crosses into the brain, where it causes trouble quickly. Astrocytes, the most abundant cells in the brain’s cortex, convert ammonia to glutamine. As glutamine builds up inside these cells, it draws in water through osmotic pressure, causing the astrocytes to swell. This swelling is one of the primary mechanisms behind the brain edema seen in severe hyperammonemia.
Animal studies have confirmed this relationship directly: when researchers blocked glutamine production in the brains of hyperammonemic rats, astrocyte swelling dropped back to normal levels, and cortical glutamine accumulation fell by roughly 70%.1PubMed Central. Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats Earlier work showed that even clinically relevant levels of ammonia can cause visible astrocyte enlargement within six hours, with the watery swelling component depending on glutamine accumulation rather than ammonia itself.2PubMed. Inhibition of glutamine synthetase reduces ammonia-induced astrocyte swelling in rat In the developing brain, the consequences can be devastating and irreversible, including cortical atrophy, loss of the insulating myelin around nerves, seizures, and cognitive impairment.3PubMed. Hyperammonemia-induced toxicity for the developing central nervous system
This is why speed matters. The longer ammonia stays elevated, the more damage accumulates. Treatment protocols are designed around this urgency, and they escalate in intensity depending on how high the ammonia is and how the patient is responding.
First-Line Emergency Interventions
When someone presents with dangerously high ammonia, the initial response involves several simultaneous actions. Protein intake is stopped immediately, because protein is the body’s main source of the nitrogen that eventually becomes ammonia. At the same time, energy intake is increased with intravenous dextrose and lipids to prevent the body from breaking down its own muscle for fuel, which would release even more ammonia.4PubMed. Dietary protein in urea cycle defects: How much? Which? How? This protein-free, high-calorie approach is typically maintained for the first 24 hours of a crisis.
Alongside metabolic support, nitrogen-scavenging drugs are started intravenously. The most established combination is sodium phenylacetate and sodium benzoate, which provide the body with alternative chemical pathways for excreting nitrogen that bypass the broken urea cycle. These drugs conjugate with amino acids in the blood, forming compounds that the kidneys can filter out. In one of the largest studies of this treatment, patients survived 96% of hyperammonemic episodes, with overall survival reaching 84% across nearly 300 patients with urea cycle disorders.5PubMed. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders
Additional agents are often given depending on the specific disorder. L-arginine is commonly administered because several urea cycle defects leave the body unable to produce enough arginine on its own, and supplementing it helps keep the remaining urea cycle function running. In cases of late-onset ornithine transcarbamylase deficiency, the full crisis management toolbox may include hemodialysis, the sodium phenylacetate/benzoate combination, L-arginine, intravenous dextrose, intralipids, and strict protein restriction, all running concurrently.6PubMed. Late-onset ornithine transcarbamylase deficiency: treatment and outcome of hyperammonemic crisis
When Dialysis Becomes Necessary
If ammonia levels remain critically elevated despite medication, or if the patient is deteriorating neurologically, dialysis enters the picture. The goal is mechanical removal of ammonia from the blood. Two main approaches are used, and they have different trade-offs. Intermittent hemodialysis clears ammonia faster and more efficiently, making it the better choice when you need the most aggressive initial reduction. However, once hemodialysis stops, ammonia from the tissues diffuses back into the blood, causing a rebound increase. Continuous renal replacement therapy clears ammonia more slowly but provides steady removal around the clock, preventing that rebound.7IntechOpen. Role of RRT in Adult Patients with Hyperammonemia
In practice, some centers use both sequentially: start with hemodialysis to rapidly knock down peak ammonia levels, then transition to continuous therapy to maintain the lower level. The choice also depends on the patient’s size and hemodynamic stability. Neonates, for example, present technical challenges for hemodialysis, and continuous methods may be more practical despite the slower clearance.
Nitrogen Scavengers for Ongoing Use
Once the acute crisis resolves, patients with urea cycle disorders typically continue on nitrogen-scavenging medications to prevent ammonia from climbing again. The oral form of these drugs is central to long-term management. Glycerol phenylbutyrate is a liquid formulation that the body breaks down into phenylbutyric acid, which is further converted to phenylacetic acid, and that compound grabs onto glutamine in the blood to form a waste product the kidneys can excrete. Studies in patients as young as two months old have confirmed that even very young infants can process this drug through its full metabolic pathway, with stable blood levels and no dangerous accumulation over time.8PubMed Central. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders
Sodium phenylbutyrate tablets are another option, though the taste and pill burden can make adherence difficult, especially in children. The choice between formulations often comes down to palatability and age. For all nitrogen scavengers, dosing is adjusted based on ammonia levels, dietary protein tolerance, and body weight, making regular blood monitoring essential.
Carglumic Acid for Specific Enzyme Deficiencies
Not all hyperammonemia responds to the same drugs. Carglumic acid fills a niche that standard nitrogen scavengers do not cover. It is a synthetic version of N-acetylglutamate, a molecule the body normally uses to activate the very first enzyme in the urea cycle. In patients with N-acetylglutamate synthase deficiency, that activating molecule is missing, and the urea cycle stalls at its starting point. Carglumic acid steps in as a direct replacement, restarting urea cycle function. For these patients, it can serve as the sole long-term treatment, maintaining metabolic control without the need for nitrogen scavengers.9Genetics in Medicine Open. Expanding clinical insight Into N-acetylglutamate synthase deficiency: A case report of diagnosis, treatment and long-term management
Beyond its original indication, carglumic acid has found a role in treating hyperammonemia caused by certain organic acidemias, including methylmalonic acidemia, propionic acidemia, and isovaleric acidemia.10PubMed Central. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency In one case involving a neonate with methylmalonic acidemia, ammonia levels dropped sharply on the second day after starting carglumic acid during the acute phase, and low-dose maintenance therapy kept ammonia under control over a full year of follow-up with normal growth and neurodevelopment.11PubMed Central. Case Report: Carglumic acid accelerates ammonia clearance in a neonate with methylmalonic acidemia These expanded uses reflect the fact that several organic acid disorders secondarily suppress N-acetylglutamate production, creating a treatable bottleneck in the urea cycle.
Managing Hyperammonemia in Liver Disease
The treatment landscape looks quite different when hyperammonemia stems from liver cirrhosis rather than an inherited enzyme deficiency. In these patients, the liver simply cannot process ammonia efficiently because so much of its tissue is scarred and nonfunctional. Portal blood carrying ammonia from the gut may also bypass the liver entirely through abnormal shunts. The resulting condition, hepatic encephalopathy, ranges from subtle cognitive slowing to full coma.
The first step is always identifying and correcting whatever tipped the patient over. Common triggers include infections, gastrointestinal bleeding (which floods the gut with protein-rich blood), dehydration, electrolyte imbalances, and constipation. More recently, malnutrition and portosystemic shunts have gained recognition as precipitating factors.12PubMed Central. Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution Finding and treating the trigger is considered the single most important aspect of managing an acute episode, because the encephalopathy often resolves once the precipitating cause is handled.13PubMed Central. Precipitating Factors and Treatment Outcomes of Hepatic Encephalopathy in Liver Cirrhosis
Lactulose and Rifaximin
The pharmacological backbone for hepatic encephalopathy targets the gut, where bacteria produce a large share of the body’s ammonia. Lactulose, a non-absorbable sugar, works by acidifying the contents of the colon, which converts ammonia into a form that cannot cross back into the bloodstream, and by speeding up bowel transit so that less ammonia is absorbed in the first place. It is typically dosed to produce two to three soft bowel movements per day.
Rifaximin is added when lactulose alone is not enough. This antibiotic stays almost entirely within the gut and reduces ammonia production by eliminating the bacteria responsible for generating it.14PubMed Central. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence It received approval for treating hepatic encephalopathy in 2010 and is valued for its minimal side effects and its ability to reduce the risk of recurrent episodes when used long-term alongside lactulose.15PubMed Central. Rifaximin in the treatment of hepatic encephalopathy Together, lactulose and rifaximin form the standard combination for both acute treatment and prevention of future episodes in people with cirrhosis.
L-Carnitine as an Adjunct
L-carnitine has attracted interest as a complementary therapy for hepatic encephalopathy. It plays a role in cellular energy metabolism, and some evidence suggests it can help lower fasting ammonia levels in cirrhotic patients. In one study of patients with hepatic encephalopathy, treatment with L-carnitine produced a significant decrease in blood ammonia.16PubMed Central. Effects of L-carnitine in patients with hepatic encephalopathy L-carnitine is not a replacement for lactulose or rifaximin, but it may offer additional benefit as part of a broader treatment regimen, particularly in patients who remain symptomatic on standard therapy.
Valproic Acid and Drug-Induced Hyperammonemia
Not all hyperammonemia comes from liver failure or genetic conditions. Valproic acid, a widely prescribed anticonvulsant and mood stabilizer, causes elevated ammonia in a substantial proportion of people who take it. One review found that roughly a third of patients on valproic acid developed hyperammonemia, with about 43% of those showing symptoms.17PubMed Central. Valproic acid–induced hyperammonemia: Incidence, clinical significance, and treatment management This is worth knowing because the symptoms of valproic acid-related hyperammonemia, including confusion, lethargy, and sometimes vomiting, can mimic a worsening of the neurological condition the drug was prescribed to treat, leading to missed diagnoses.
Treatment options for this specific scenario differ from those used in urea cycle disorders. Stopping the valproic acid was the most effective approach, resolving the problem in about 56% of cases. Lactulose was the most commonly tried pharmacological intervention but had a lower success rate of about 42%. L-carnitine supplementation, which some clinicians prescribe because valproic acid depletes carnitine stores, succeeded in about half of cases but did not show a statistically significant advantage over other approaches in that analysis. When valproic acid is the culprit, the most important clinical decision is whether the drug can be switched to a different medication, which removes the underlying cause entirely.
TIPS-Related Hyperammonemia
Transjugular intrahepatic portosystemic shunt placement is a procedure used to relieve dangerous portal hypertension in people with advanced liver disease. The shunt reroutes blood flow around the scarred liver, which solves the pressure problem but creates a new one: blood carrying ammonia from the gut now bypasses the liver’s remaining detoxification capacity more than it already did. Hepatic encephalopathy is a well-recognized complication of TIPS, and ammonia levels measured before and after the procedure may help predict who will develop it.18PubMed Central. Plasma Ammonia Levels Predict Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement Management of TIPS-related encephalopathy follows the same principles as other hepatic encephalopathy, with lactulose and rifaximin forming the pharmacological core.19PubMed Central. Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges In refractory cases, the shunt diameter can sometimes be reduced or the shunt occluded, though this reintroduces the portal hypertension that necessitated the TIPS in the first place.
Monitoring Ammonia Levels
Managing hyperammonemia over time requires reliable and frequent ammonia measurement, which is more complicated than it sounds. Ammonia in a blood sample starts to degrade and change within minutes of the draw, which means samples must be kept cold and analyzed quickly. Hospital laboratory turnaround times can introduce enough delay to make results unreliable, leading to clinical decisions based on stale numbers.
This has driven interest in point-of-care testing devices that can measure ammonia at the bedside. A recent validation study of an automated point-of-care analyzer found that it was comparable to standard hospital laboratory methods, with a mean measurement error of only about 4% and a small positive bias of roughly 6 micromoles per liter.20PubMed Central. Testing of a novel automated point-of-care analyzer for blood ammonium monitoring in a clinical setting If such devices become widely adopted, they could allow for much tighter ammonia monitoring, especially during acute crises when levels can change rapidly and treatment adjustments need to happen in real time.
For patients with severe hyperammonemic crises who are in the intensive care unit, monitoring extends well beyond blood ammonia. Serial brain monitoring using electroencephalography, transcranial Doppler ultrasound, and near-infrared spectroscopy can track neurological status and cerebral blood flow as treatment progresses.21PubMed Central. Late-onset ornithine transcarbamylase deficiency with neurological damage and serial brain multimodality monitoring: a case report In some cases, direct intracranial pressure monitoring is used, which has shown pressure spikes as high as 60 mmHg in children during hyperammonemic crises, information that directly guides decisions about brain-protective treatments like osmotic therapy.22PubMed Central. Intracranial Pressure Monitoring Demonstrates that Cerebral Edema Is Not Correlated to Hyperammonemia in a Child with Ornithine Transcarbamylase Deficiency
Liver Transplantation as a Cure
For patients with urea cycle disorders, liver transplantation remains the only curative option currently available. Because the urea cycle enzymes are produced in the liver, replacing the organ with one from a healthy donor restores full enzyme function. A nationwide study from Japan confirmed that liver transplant was effective for long-term survival, prevented recurrent hyperammonemic attacks, and lowered baseline blood ammonia levels in patients with urea cycle disorders.23PubMed. Role of liver transplantation in urea cycle disorders: Report from a nationwide study in Japan Living-donor transplantation has also been documented as curative in adult-onset cases, including patients who were not diagnosed until a metabolic crisis unmasked the deficiency later in life.24PubMed Central. Carbamoyl phosphate synthetase 1 deficiency manifested in an adult treated with prednisone for polymyositis, and cured by live-donor liver transplantation
Transplantation is not a decision taken lightly. It carries surgical risks, requires lifelong immunosuppression, and depends on organ availability. For patients who are metabolically stable on medication and dietary management, the risks of transplant may outweigh the benefits, at least in the short term. But for those with frequent crises, poor metabolic control despite optimized medical therapy, or deteriorating neurodevelopment, transplant can be genuinely life-changing. The timing of transplant is a recurring subject of debate in metabolic medicine, since waiting too long risks accumulating brain injury that transplant cannot reverse, while operating too early may expose stable patients to unnecessary surgical risk.
Gene Therapy and RNA-Based Approaches
The limitations of current treatments, particularly the fact that nitrogen scavengers manage symptoms without fixing the underlying genetic defect, have driven decades of work toward gene-based cures. Over the past 30 years, researchers have explored adenoviral vectors, adeno-associated viral vectors, gene editing, and genome integration techniques as potential approaches to delivering working copies of urea cycle genes to the liver.25PubMed Central. Gene therapy for urea cycle defects: An update from historical perspectives to future prospects
More recently, messenger RNA therapy delivered via lipid nanoparticles has emerged as a promising alternative. Unlike gene therapy, which aims to permanently alter the cell’s DNA, mRNA therapy provides temporary instructions for the cell to produce the missing enzyme, requiring repeated dosing but avoiding some of the safety concerns associated with permanent genetic changes. This approach has been tested in preclinical models for several urea cycle disorders, including citrullinemia type I, argininosuccinic aciduria, and arginase deficiency. For ornithine transcarbamylase deficiency, the most common urea cycle disorder, mRNA therapy has moved beyond animal studies and entered clinical trials.26PubMed Central. Exploring RNA therapeutics for urea cycle disorders These trials are still in early stages, but they represent the closest anyone has come to a non-surgical molecular correction for the most common inherited cause of hyperammonemia.
Late-Onset and Undiagnosed Cases
One of the trickiest aspects of hyperammonemia is that the underlying metabolic disorder can remain hidden for years or decades, only surfacing when the body is pushed past a metabolic tipping point. Late-onset urea cycle disorders, particularly partial ornithine transcarbamylase deficiency in women, can present for the first time during physiological stress events like surgery, illness, high-protein diets, or the postpartum period. Postpartum episodes are especially treacherous because the confusion and altered behavior can be mistaken for postpartum psychosis, delaying the metabolic workup that would reveal the true cause.
These cases underscore why ammonia should be checked in any patient with unexplained encephalopathy, regardless of age or apparent liver health. A simple blood ammonia level, drawn properly and analyzed quickly, can redirect the diagnostic workup entirely. For adults newly diagnosed with a urea cycle disorder after a crisis, the long-term management plan follows the same principles as for patients diagnosed in childhood: nitrogen scavengers or carglumic acid depending on the specific defect, dietary protein management, close monitoring, and consideration of liver transplantation if metabolic control proves difficult to maintain.